Real-World Durability of Effectiveness Through 24 Months of Anti-IL-17A Biologics and Other Approved Biologics in Treating Patients With Moderate-to-Severe Psoriasis in the PSoHO


Por: Tjioe, M, Costanzo, A, Carrascosa, JM, Bovenschen, HJ, Maul, JT, de Hoog, N, Martimianaki, G, Lampropoulou, A, Mckenzie, R, Pinter, A and Fotiou, K

Publicada: 1 abr 2025
Resumen:


Filiaciones:
Tjioe, M:
 Bravis Hosp, DermaTeam Res, Roosendaal, Netherlands

Costanzo, A:
 Univ Milan, Dept Human Anat, Milan, Italy

:
 Univ Autonoma Barcelona, Hosp Universitari Germans Trias i Pujol, Cardiol Dept, Badalona, Barcelona, Spain

Bovenschen, HJ:
 Maxima Med Ctr, Veldhoven, Netherlands

Maul, JT:
 Univ Hosp Zurich, Zurich, Switzerland

de Hoog, N:
 Eli Lilly & Co, Indianapolis, IN USA

Martimianaki, G:
 Eli Lilly & Co, Indianapolis, IN USA

Lampropoulou, A:
 Eli Lilly & Co, Indianapolis, IN USA

Mckenzie, R:
 Eli Lilly & Co, Indianapolis, IN USA

Pinter, A:
 Univ Hosp Frankfurt, Frankfurt, Germany

Fotiou, K:
 Lilly Deutschland GmbH, Bad Homburg, Germany
ISSN: 16100379





JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Meeting Abstract
Volumen: 23 Número:
Páginas:
WOS Id: 001515598600165

MÉTRICAS